[雷特格韦：首个HIV整合酶抑制剂。引言] - Suppr

Suppr

超能文献

[Raltegravir: the first HIV integrase inhibitor. Introduction].

作者信息

Gatell José M

机构信息

Servicio de Infecciones, Hospital Clinic, IDIBAPS, Universidad de Barcelona, Barcelona, España.

出版信息

Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:1-2. doi: 10.1016/s0213-005x(08)76565-0.

DOI:10.1016/s0213-005x(08)76565-0

PMID:19572418

Abstract

摘要

相似文献

[Raltegravir: the first HIV integrase inhibitor. Introduction].

Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:1-2. doi: 10.1016/s0213-005x(08)76565-0.

[Efficacy of raltegravir: from healthy volunteers to phase III trials].

Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:29-33. doi: 10.1016/s0213-005x(08)76570-4.

[How proviral DNA is integrated into the host cell DNA and how this process can be inhibited].

Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:11-6. doi: 10.1016/s0213-005x(08)76567-4.

Targeting the HIV integration process in antiviral therapy.

J HIV Ther. 2008 Dec;13(4):83-92.

Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.

Expert Opin Drug Metab Toxicol. 2010 Sep;6(9):1151-60. doi: 10.1517/17425255.2010.513383.

Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility.

AIDS. 2008 Sep 12;22(14):1877-80. doi: 10.1097/QAD.0b013e32830f9703.

Resistance to inhibitors of the human immunodeficiency virus type 1 integration.

Braz J Infect Dis. 2010 Sep-Oct;14(5):513-8.

Integrase inhibitors in the treatment of HIV-1 infection.

J Antimicrob Chemother. 2010 Dec;65(12):2485-8. doi: 10.1093/jac/dkq350. Epub 2010 Sep 18.

HIV-1 integrase inhibitors: update and perspectives.

Adv Pharmacol. 2008;56:199-228. doi: 10.1016/S1054-3589(07)56007-2.

Novel integrase inhibitors for HIV.

Expert Opin Investig Drugs. 2010 Sep;19(9):1087-98. doi: 10.1517/13543784.2010.501078.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

[Raltegravir: the first HIV integrase inhibitor. Introduction].

Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:1-2. doi: 10.1016/s0213-005x(08)76565-0.

[Efficacy of raltegravir: from healthy volunteers to phase III trials].

Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:29-33. doi: 10.1016/s0213-005x(08)76570-4.

[How proviral DNA is integrated into the host cell DNA and how this process can be inhibited].

Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:11-6. doi: 10.1016/s0213-005x(08)76567-4.

Targeting the HIV integration process in antiviral therapy.

J HIV Ther. 2008 Dec;13(4):83-92.

Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.

Expert Opin Drug Metab Toxicol. 2010 Sep;6(9):1151-60. doi: 10.1517/17425255.2010.513383.

Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility.

AIDS. 2008 Sep 12;22(14):1877-80. doi: 10.1097/QAD.0b013e32830f9703.

Resistance to inhibitors of the human immunodeficiency virus type 1 integration.

Braz J Infect Dis. 2010 Sep-Oct;14(5):513-8.

Integrase inhibitors in the treatment of HIV-1 infection.

J Antimicrob Chemother. 2010 Dec;65(12):2485-8. doi: 10.1093/jac/dkq350. Epub 2010 Sep 18.

HIV-1 integrase inhibitors: update and perspectives.

Adv Pharmacol. 2008;56:199-228. doi: 10.1016/S1054-3589(07)56007-2.

Novel integrase inhibitors for HIV.

Expert Opin Investig Drugs. 2010 Sep;19(9):1087-98. doi: 10.1517/13543784.2010.501078.